Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center

Abstract 3120▪▪This icon denotes a clinically relevant abstract Chemo-immunotherapy (i.e. rituximab combinations) has clearly had a significant impact on the outcome of all B-cell NHL both in terms of PFS and OS. However in the relapse/refractory setting a large proportion of pts still do very poorl...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2012-11, Vol.120 (21), p.3120-3120
Main Authors: Mato, Anthony R, Waksmundzki, Kathryn, Zielonka, Tania, Protomastro, Ewelina A, Amatucci, Theresa, Rosario, Maria, Goldberg, Stuart L., Feldman, Tatyana, Rowley, Scott D, Donato, Michele L., Timberg, Mary, Baker, Melissa F, Sutherland, Pam, McKiernan, Phyllis, Pecora, Andrew L, Goy, Andre
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 3120▪▪This icon denotes a clinically relevant abstract Chemo-immunotherapy (i.e. rituximab combinations) has clearly had a significant impact on the outcome of all B-cell NHL both in terms of PFS and OS. However in the relapse/refractory setting a large proportion of pts still do very poorly especially in aggressive subtypes including DLBCL and MCL. Salvage therapy followed by HDT-ASCT in relapsed DLBCL remains the standard, though pts with early failures (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V120.21.3120.3120